Related Experiment Video
Updated: Mar 8, 2026

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
microRNA-132: a key noncoding RNA operating in the cellular phase of Alzheimer's disease
Evgenia Salta1,2, Bart De Strooper3,2,4
1Vlaams Instituut voor Biotechnologie (VIB) Center for Brain and Disease, VIB-Leuven, Leuven, Belgium; evgenia.salta@cme.vib-kuleuven.be.
Abstract:
With the consideration of the broad involvement of microRNAs (miRNAs) in the regulation of molecular networks in the brain, it is not surprising that miRNA dysregulation causes neurodegeneration in animal models. miRNA profiling in the human brain has revealed miR-132 as one of the most severely down-regulated miRNAs at the intermediate and late Braak stages of Alzheimer's disease (AD), as well as in other neurodegenerative disorders. Suppression of miR-132 aggravates multiple layers of pathology at the molecular and functional level. We describe the potential therapeutic implications of these findings and suggest miRNA targeting or replacement as a realistic multi-hit, therapeutic strategy for AD. Salta, E., De Strooper, B. microRNA-132: a key noncoding RNA operating in the cellular phase of Alzheimer's disease.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
MicroRNAs
MicroRNAs
Alzheimer's Disease: Treatment

